期刊
VACCINE
卷 26, 期 24, 页码 3008-3015出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.12.023
关键词
HIV-1; chemokines; RANTES; chemokine receptors; CCR5; inhibitors; rational design
资金
- NIAID NIH HHS [U19 AI060615, U19 AI060615-04, U19 AI60615] Funding Source: Medline
The discovery that the CC chemokines RANTES, MIP-1 alpha and MIP-1 beta act as potent natural inhibitors of HIV-1, the causative agent of AIDS, and the subsequent identification of CCR5 as a major virus coreceptor have triggered a wealth of basic and applied research approaches aimed at developing safe and effective viral entry inhibitors. Some of these efforts have focused on RANTES engineering with the goal of enhancing the antiviral activity of the native molecute while reducing or abrogating its inflammatory properties. The wavefront generated a decade ago is still on its course, with a flow of promising leads constantly emerging and being evaluated in preclinical studies. Here, we present an overview of this rapidly evolving field, highlighting the most important features of RANTES molecular architecture and structure-function retationships. (c) 2007 Elsevier Ltd. AR rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据